Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Clark

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Pilot and Feasibility Studies|September 27, 2025
Control, Fludrocortisone or Midodrine for the treatment of Orthostatic Hypotension (CONFORM-OH): results from an internal pilot randomised controlled trialHelen Mossop, Sarah Al-Ashmori, Tumi Sotire, et al.
British Journal of Cancer|April 8, 2021
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancerJosé Bines, Emma Clark, Claire Barton, et al.
The New England Journal of Medicine|June 6, 2017
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast CancerGunter von Minckwitz, Marion Procter, Evandro de Azambuja, et al.
NIHR Open Research|October 25, 2023
Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trialPaul Gravestock, Emma Clark, Miranda Morton, et al.
Blood|March 2, 2026
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trialJeff P Sharman, Luca Laurenti, Emmanuelle France Ferrant, et al.
BMJ Open|August 19, 2021
Improving uptake of Fracture Prevention drug treatments: a protocol for Development of a consultation intervention (iFraP-D)Zoe Paskins, Laurna Bullock, Fay Crawford-Manning, et al.
The New England Journal of Medicine|December 12, 2022
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell LymphomaMichael J Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, et al.
NPJ Microgravity|March 6, 2024
Microgravity effects on nonequilibrium melt processing of neodymium titanate: thermophysical properties, atomic structure, glass formation and crystallizationStephen K Wilke, Abdulrahman Al-Rubkhi, Chihiro Koyama, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trialRichard D Gelber, Xin V Wang, Bernard F Cole, et al.
BMJ Open|September 5, 2019
Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectivenessZafer Tandogdu, Rebecca Lewis, Anne Duncan, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Pilot and Feasibility Studies|September 27, 2025
Control, Fludrocortisone or Midodrine for the treatment of Orthostatic Hypotension (CONFORM-OH): results from an internal pilot randomised controlled trialHelen Mossop, Sarah Al-Ashmori, Tumi Sotire, et al.
British Journal of Cancer|April 8, 2021
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancerJosé Bines, Emma Clark, Claire Barton, et al.
The New England Journal of Medicine|June 6, 2017
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast CancerGunter von Minckwitz, Marion Procter, Evandro de Azambuja, et al.
NIHR Open Research|October 25, 2023
Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trialPaul Gravestock, Emma Clark, Miranda Morton, et al.
Blood|March 2, 2026
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trialJeff P Sharman, Luca Laurenti, Emmanuelle France Ferrant, et al.
BMJ Open|August 19, 2021
Improving uptake of Fracture Prevention drug treatments: a protocol for Development of a consultation intervention (iFraP-D)Zoe Paskins, Laurna Bullock, Fay Crawford-Manning, et al.
The New England Journal of Medicine|December 12, 2022
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell LymphomaMichael J Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, et al.
NPJ Microgravity|March 6, 2024
Microgravity effects on nonequilibrium melt processing of neodymium titanate: thermophysical properties, atomic structure, glass formation and crystallizationStephen K Wilke, Abdulrahman Al-Rubkhi, Chihiro Koyama, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trialRichard D Gelber, Xin V Wang, Bernard F Cole, et al.
BMJ Open|September 5, 2019
Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectivenessZafer Tandogdu, Rebecca Lewis, Anne Duncan, et al.
Pageof 10